Application of RINL gene and antagonist thereof in obesity treatment

Through the RINL gene and its antagonists as targets for obesity, drugs for obesity treatment have been developed, which has solved the willpower dependence and side effects of existing treatment methods, achieved the effect of improving metabolism and reducing diabetes risk, and provided Possibility of a new generation of obesity treatment.

CN118949034APending Publication Date: 2024-11-15XIAMEN UNIV
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411039974.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing obesity treatment methods have problems such as willpower dependence, high postoperative risks, and greater side effects. They lack effective targets, resulting in unstable efficacy and greater side effects.

Method used

By exploring RINL genes and their antagonists as new targets for obesity, using gene knockout and gene therapy technologies to inhibit RINL expression, develop drugs for diagnosing, detecting and treating obesity, improving metabolic capacity and reducing diabetes risk .

Benefits of technology

RINL-KO mice can resist obesity caused by a high-fat diet, improve metabolic ability and glucose tolerance, and reduce fat tissue, providing a new idea for efficient obesity treatment and important new drug screening significance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004972134690000051
    Figure BDA0004972134690000051
  • Figure BDA0004972134690000081
    Figure BDA0004972134690000081
  • Figure BDA0004972134690000111
    Figure BDA0004972134690000111
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to an application of an RINL gene and an antagonist thereof in obesity treatment. Specifically, the invention provides an application of an RINL gene or an encoding protein thereof, and the RINL gene or the encoding protein thereof: (1) is used as a marker for diagnosis, detection or prognosis of obesity; (2) preparing a reagent or a kit for diagnosing or detecting obesity; or (3) preparing a medicine for treating obesity. The RINL-KO obviously improves the glucose tolerance condition and the insulin resistance degree of obese mice, improves the accumulation condition of subcutaneous fat and visceral fat of the obese mice, relieves adipose tissue verification of the obese mice, and greatly improves the health degree of the mice. Therefore, the RINL antagonist has the potential of efficiently treating obesity. Therefore, the invention proposes that the RINL is used for preparing a new target of the medicine for treating obesity for the first time, has important significance for screening new medicines, and also provides a new thought for treating obesity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of RINL gene and its antagonist in the treatment of obesity. Background Art

[0002] With the improvement of living standards and changes in lifestyle, obesity is becoming a huge threat to human health. The main pathological manifestation of obesity is that the percentage of body fat in body weight is too high, and there may also be enlarged fat cells, and it is usually accompanied by symptoms of glucose and lipid metabolism imbalance such as hyperglycemia and hyperlipidemia, which leads to diabetes. At present, the main treatments for obesity are drug therapy, surgery and life intervention, but all three methods have certain shortcomings. For example, life intervention mainly makes the body's energy expenditure greater than input through diet and exercise. However, long-term regular life depends on the patient's willpower. For many people with weak willpower, the effect is unstable and easy to rebound. Surgical treatment mainly increases satiety by reducing the volume of the stomach or filling air bags in the stomach, thereby reducing energy intake and achieving the effect of treatment. However, there are problems such as high postoperative risks and possible malnutrition, and few people can receive treatment. At present, drug treatment mainly includes drugs such as orlistat and lorcaserin, which have relatively stable efficacy, but due to the lack of good targets, its side effects are large, such as orlistat may cause incontinence. With the development of gene therapy technology and a deeper understanding of genes related to glucose and lipid metabolism, it is becoming increasingly feasible to find new targets at the genetic level to treat obesity.

[0003] RINL (the full name of which is Ras And Rab Interactor Like) is involved in a variety of biological processes in cells, especially those related to vesicle-mediated transport and the regulation of Rab proteins. The protein expressed by RINL can activate the small GTPase of the Rab5 subfamily, thereby playing a role in endocytosis. RINL is expressed in a variety of tissues, especially in the thymus and spleen, where the expression level is higher. During the experiment, the applicant unexpectedly discovered that the RINL gene may be related to obesity. Based on this, the present application explores the relationship between the RINL gene and obesity and metabolism, and its potential for application in the development of obesity drugs. Summary of the invention

[0004] In order to solve the problems existing in the prior art, the purpose of the present disclosure is to provide the use of RINL gene and its antagonist in the treatment of obesity.

[0005] In order to achieve the above objectives, the present disclosure adopts the following specific scheme:

[0006] In one aspect, the present disclosure provides uses of the RINL gene or its encoded protein, wherein the RINL gene or its encoded protein is: (1) used as a marker for diagnosing, detecting or prognosing obesity; (2) used to prepare a reagent or kit for diagnosing or detecting obesity; or (3) used to prepare a drug for treating obesity.

[0007] In another aspect, the present disclosure provides the use of a RINL antagonist in the preparation of a medicament for: (1) preventing and / or treating obesity; (2) improving the metabolic capacity of obese patients; (3) preventing and / or reducing the risk of diabetes in obese patients; or (4) improving the immune function of obese patients.

[0008] In another aspect, the present disclosure provides a method for screening drugs for treating and / or preventing obesity, comprising the following steps of detecting changes in the expression level of RINL gene in the body before and after administration.

[0009] In another aspect, the present disclosure provides a pharmaceutical composition for treating and / or preventing obesity, comprising a RINL antagonist that inhibits RINL expression, and optionally a pharmaceutically acceptable carrier or excipient.

[0010] The beneficial effects of the present disclosure are at least as follows:

[0011] The present invention establishes a high-fat diet to induce obesity in mice, uses gene knockout and gene therapy technology, takes RINL as a target, and knocks down the expression of RINL throughout the body to explore the possibility of using RINL as a target for gene therapy to treat obesity. The results show that RINL-KO can resist obesity caused by a high-fat diet, improve the body fat percentage of mice, do not affect the food intake of mice, and improve the metabolic capacity of obese mice. In addition, RINL-KO significantly improves the glucose tolerance and insulin resistance of obese mice, improves the accumulation of subcutaneous fat and visceral fat, reduces the verification of its adipose tissue, and greatly improves the health of mice. Therefore, RINL antagonists have the potential to effectively treat obesity. Therefore, the present invention proposes for the first time to use RINL as a new target for the preparation of drugs for the treatment of obesity, which is of great significance for screening new drugs and provides a new idea for the treatment of obesity. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 The correlation between the transcript level of RINL in human subcutaneous adipose tissue and total cholesterol and triglycerides is shown.

[0013] Figure 2 The expression of RINL in mouse adipocyte model and obesity mouse model is shown.

[0014] Figure 3The figure shows the effect of knocking down the expression of RINL in HepG2 cells using siRNA on cellular lipid metabolism.

[0015] Figure 4 The figure shows the body weight changes of male and female mice in different groups during 13 weeks of high-fat feeding.

[0016] Figure 5 Shown are the metabolic effects of RINL-KO on high-fat diet mice (24 months old).

[0017] Figure 6 The OGTT test results of male and female mice in different groups are shown.

[0018] Figure 7 The ITT test results of male and female mice in different groups are shown.

[0019] Figure 8 The morphology of various tissues in mice fed a high-fat diet is shown.

[0020] Fig. 9 The proportion of each organ in male and female mice fed a high-fat diet is shown.

[0021] Fig.10 HE sections of liver and adipose tissue from male and female mice are shown.

[0022] Fig.11 The accumulation of gonadal fat in male and female mice is shown.

[0023] Fig.12 Oil red-stained sections of liver tissue and fluorescent staining results of adipose tissue are shown.

[0024] Fig.13 The results of oxygen consumption measurement of brown adipose tissue and liver tissue are shown. Among them, pyruvate (pyr) + malate (malate, mal) is a substrate of mitochondrial complex I, succinate (Suc) is a substrate of mitochondrial complex II, rotenone (Rot) is a mitochondrial complex I inhibitor, and antimycin (Ant) is a mitochondrial complex III inhibitor. Ascorbic acid (Asc) + N,N,N′,N′-tetramethyl-para-phenylene-diamine (TMPD) is a substrate of mitochondrial complex IV.

[0025] Fig.14The oxygen consumption rate of primary brown fat cells is shown. Oligomycin (Oli) is an ATP synthase inhibitor, Rotenone (Rot) is a mitochondrial complex I inhibitor, Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) is a mitochondrial uncoupler, Rotenone (Rot) is a mitochondrial complex I inhibitor, and Antimycin (Ant) is a mitochondrial complex III inhibitor. DETAILED DESCRIPTION

[0026] I. Terminology

[0027] In order to make the present disclosure more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by those skilled in the art to which the present disclosure belongs.

[0028] As used herein, the articles "a" and "an" refer to one or more than one (ie, at least one) of the grammatical object to which the article refers. For example, "an element" means one element or more than one element.

[0029] As used herein, "diabetes" refers to a group of diseases that broadly involve the inability to properly regulate the use of glucose or sugar as a result of defects in the production, secretion or function of the hormone insulin. Abnormal function of insulin leads to abnormal metabolism of carbohydrates, fats and proteins. Diabetes is divided into two common types. Type 1 or insulin-dependent diabetes is caused by an autoimmune reaction that causes the destruction of the insulin-producing beta islet cells in the pancreas, resulting in a systemic lack of insulin. The treatment of this disease mainly consists of regular monitoring of blood sugar levels and injections of insulin several times a day. Failure to control insulin dosage can lead to severe hypoglycemia and life-threatening damage to the brain and other functions.

[0030] Type 2 or non-insulin-dependent diabetes mellitus (T2DM) is a more complex disease that usually develops in adults and is associated with glucose-responsive tissues (such as fatty adipose tissue, muscle, and liver) that become resistant to the effects of insulin. In the early stages of T2DM, pancreatic islet cells compensate by secreting excess insulin. Without intervention, beta islet cell dysfunction results, leading to decompensation and chronic hyperglycemia. In addition, T2DM may also be accompanied by peripheral insulin resistance, in which otherwise insulin-sensitive cells fail to respond normally. While type 1 diabetes is usually an acute disease that develops early in life, type 2 diabetes can develop gradually later in life due to a number of factors, including genetics and lifestyle. The following classes of drugs are commonly used to treat T2DM: 1) insulin-releasing agents that directly stimulate insulin secretion but carry the risk of causing hypoglycemia; 2) a dietary insulin-releasing agent that enhances glucose-induced insulin secretion but must be taken before each meal; 3) biguanides, including metformin, which reduce glucose produced by digestion; 4) insulin sensitizers, such as the thiazolidinedione derivatives rosiglitazone and pioglitazone, which improve peripheral responses to insulin by regulating the expression of glucose metabolism genes but have side effects such as weight gain, edema, and hepatotoxicity; and 5) insulin injections, which are usually required in advanced T2DM.

[0031] The metabolic nature of type 2 diabetes and the abnormally high blood sugar levels resulting from the condition often lead to the development of symptoms and disorders that affect a wide range of body tissues. Diabetes is associated with a high incidence of obesity, fatty liver disease, hyperlipidemia, fatty liver disease, and GI motility disorders, including gastroparesis and constipation.

[0032] T2DM-associated insulin resistance is often associated with atherosclerosis, obesity, hyperlipidemia, and essential hypertension. This group of abnormal conditions constitutes "metabolic" or insulin resistance. In addition, insulin resistance is associated with fatty liver disease, which may lead to chronic inflammation or non-alcoholic steatohepatitis, fibrosis, and cirrhosis. Non-alcoholic fatty liver disease begins with the accumulation of triglycerides in the liver and is defined as the presence of cytoplasmic lipid droplets in more than 5% of hepatocytes or TAG levels exceeding the 95th percentile of healthy individuals. Both T2DM and fatty liver disease share comorbidities and adversely affect the progression of their respective diseases. Type 2 diabetes is a risk factor for progressive liver disease and liver-related death in patients with fatty liver disease, and fatty liver disease may be a marker of cardiovascular risk and mortality in individuals with type 2 diabetes. Non-alcoholic steatohepatitis, a histological subtype of NAFLD characterized by hepatocellular damage and inflammation, is present in approximately 10% of patients with T2DM and is associated with an increased risk of development of cirrhosis and liver-related death.

[0033] Diabetic gastroparesis is a common but serious chronic upper gastrointestinal disorder defined as delayed gastric emptying in the absence of physical obstruction and associated with symptoms such as nausea, vomiting, early satiation, bloating, and abdominal pain. Currently, the only FDA-approved drug for the treatment of diabetic gastroparesis is metoclopramide, a dopamine D2 receptor antagonist and 5-HT3 receptor antagonist with weak 5-HT4 agonist activity, which is indicated for relief of symptoms associated with acute and recurrent diabetic gastric stasis due to treatment for no more than 12 weeks. However, metoclopramide treatment is associated with significant side effects such as sudden muscle cramps and depression / mood changes.

[0034] As used herein, "RINL" stands for Ras And Rab Interactor Like, which is involved in a variety of biological processes in cells, especially related to vesicle-mediated transport and the regulation of Rab proteins. The protein expressed by RINL can activate the Rab5 subfamily small GTPase, thereby playing a role in endocytosis. RINL is expressed in a variety of tissues, especially in the thymus and spleen, where the expression level is high.

[0035] As used herein, the term "BAT" refers to Brown Adipose Tissue, which is a special type of adipose tissue whose main function is to produce heat to maintain body temperature. Unlike white adipose tissue (WAT), which is mainly responsible for storing energy, BAT contains a large number of mitochondria and uncoupling protein 1 (UCP1), which makes it play an important role in energy metabolism. BAT is mainly distributed in the body's shoulder blades, neck, armpits, mediastinum and around the kidneys, especially in infants, while the BAT content in adults is relatively low, accounting for only about 1%-2%1.

[0036] As used herein, the term "GWAT" is Gonadal White Adipose Tissue, which refers to gonadal white adipose tissue, which is a special type of white adipose tissue that is mainly distributed around reproductive organs, such as testicles and ovaries. In addition to storing energy, GWAT can secrete some hormones and cytokines and may also participate in local immune responses.

[0037] As used herein, the term "Oil Red O staining" is a commonly used chemical detection technique for detecting and quantifying lipids in tissues, particularly neutral fats (triglycerides). Oil Red O is a fat-soluble dye that binds to fatty acids and triglyceride molecules in tissue sections. During the staining process, Oil Red O dye penetrates into cells containing lipids, particularly adipocytes, and binds to lipid droplets. Since Oil Red O dye has a red color, cells containing lipids appear red or pink when observed under a microscope, while cells without lipids will not be colored.

[0038] As used herein, the expressions "cell," "cell line," and "cell culture" are used interchangeably, and all such names include progeny thereof. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It should also be understood that all progeny may not be exactly identical in terms of DNA content, due to intentional or unintentional mutations. Mutant progeny having the same function or biological activity as screened for in the originally transformed cell are included. Where different names are intended, this is clear from the context.

[0039] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and where it does not occur.

[0040] The term "knockout mouse" refers to a mouse that has an existing gene inactivated (i.e., "knocked out"). In some embodiments, the gene is inactivated by homologous recombination. In some embodiments, the gene is inactivated by replacement or disruption with an artificial nucleic acid sequence.

[0041] "Administering," "giving," and "treating" when applied to animals, humans, experimental subjects, cells, tissues, organs, or biological fluids, refers to the contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with an animal, human, subject, cell, tissue, organ, or biological fluid. "Administering," "giving," and "treating" can refer to, for example, treatment, pharmacokinetics, diagnosis, research, and experimental procedures. Treatment of cells includes contact of an agent with a cell, and contact of an agent with a fluid, wherein the fluid is in contact with the cell. "Administering," "giving," and "treating" also mean in vitro and ex vivo treatment of, for example, a cell, by an agent, a diagnosis, a combination composition, or by another cell. "Treatment," when applied to humans, veterinary medicine, or research subjects, refers to therapeutic treatment, prophylactic or preventative measures, research and diagnostic applications.

[0042] "Treatment" means administering an internal or external therapeutic agent to a patient who has one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Generally, the therapeutic agent is administered in an amount effective to alleviate one or more symptoms of a disease in the patient or population being treated, either by inducing regression of such symptoms or inhibiting the progression of such symptoms to any clinically unmeasurable degree. The amount of a therapeutic agent effective to alleviate any specific disease symptom (also referred to as a "therapeutically effective amount") may vary according to a variety of factors, such as the disease state, age, and weight of the patient, and the ability of the drug to produce the desired therapeutic effect in the patient. Whether a disease symptom has been alleviated may be assessed by any clinical test method commonly used by a physician or other health care professional to assess the severity or progression of the symptom. Although the embodiments of the present disclosure (e.g., treatment methods or articles of manufacture) may not be effective in alleviating the symptoms of the target disease in every patient, they should alleviate the symptoms of the target disease in a statistically significant number of patients as determined by any statistical test known in the art, such as Student's t-test, chi-square test, U test according to Mann and Whitney, Kruskal-Wallis test (H test), Jonckheere-Terpstra test, and Wilcoxon test.

[0043] The term "consisting essentially of" or variations thereof as used throughout the specification and claims means including all recited elements or groups of elements, and optionally including other elements of similar or different properties to the recited elements, which other elements do not significantly alter the basic or novel properties of a specified dosing regimen, method, or composition.

[0044] The term "antagonist" refers to a substance that can act at the nucleic acid or protein level to reduce or inhibit the expression or activity of RINL, including but not limited to shRNA, siRNA, miRNA, dsRNA, small molecule compounds, stRNA, aptamers, or antibodies or their antigen-binding fragments.

[0045] A "vector" is a composition of matter that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid into a cell. Many vectors are known in the art, including but not limited to linear polynucleotides, polynucleotides associated with ions or amphipathic compounds, plasmids and viruses. Therefore, the term "vector" includes an autonomously replicating plasmid or virus. The term should also be interpreted to include non-plasmid and non-viral compounds that promote the transfer of nucleic acids into cells, such as, for example, polylysine compounds, liposomes, etc. Examples of viral vectors include but are not limited to adenoviral vectors, adeno-associated viral vectors, retroviral vectors, etc.

[0046] The terms "patient," "subject," "individual," and the like are used interchangeably herein and are intended to include living organisms (e.g., mammals) in which an immune response can be elicited. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof.

[0047] The term "kit" is any product (e.g., a package or container) containing at least one reagent (e.g., a therapeutic agent, a probe, a small molecule, etc.) for specific detection and / or therapeutically affecting the expression of the markers described in the present invention. The kit can be promoted, distributed or sold as a whole for performing the method described in the present invention. The kit may contain one or more reagents, which are necessary for the expression of the composition used in the method described in the present invention. In certain embodiments, the kit may further contain a reference standard, for example, a nucleic acid encoding a protein that does not affect or regulate a signaling pathway that controls an immune response, cell growth, division, migration, survival or apoptosis. A person skilled in the art can envision many such control proteins, including but not limited to: common molecular tags (e.g., green fluorescent protein and β-galactosidase); proteins that are not included in the classification of any pathway including cell growth, division, migration, survival or apoptosis by GeneOntology reference; or ubiquitous housekeeping proteins. The reagents in the kit may be provided by a single container, or by a mixture of two or more reagents in a single container. In addition, explanatory materials describing the use of the composition in the kit may be included.

[0048] The term "prognosis" refers to the act of predicting the course and outcome of a disease in advance. More specifically, the course of a disease after treatment may vary depending on the patient's physiological or environmental conditions, and it can be interpreted as all actions that predict the course of a disease after treatment, taking into account the patient's overall condition. For the purposes of this disclosure, prognosis prediction can be interpreted as predicting the disease-free survival rate of obese patients by predicting the course of the disease and the situation after treatment of obese patients.

[0049] Abbreviations

[0050]

[0051]

[0052] II. Detailed description of specific implementation scheme

[0053] In one aspect, the present disclosure provides uses of the RINL gene or its encoded protein, wherein the RINL gene or its encoded protein is: (1) used as a marker for diagnosing, detecting or prognosing obesity; (2) used to prepare a reagent or kit for diagnosing or detecting obesity; or (3) used to prepare a drug for treating obesity.

[0054] In another aspect, the present disclosure provides the use of a RINL antagonist in the preparation of a medicament for: (1) preventing and / or treating obesity; (2) improving the metabolic capacity of obese patients; (3) preventing and / or reducing the risk of diabetes in obese patients; or (4) improving the immune function of obese patients.

[0055] In some embodiments, the RINL antagonist specifically targets the nucleotide sequence shown in SEQ ID NO.1 or specifically binds to the amino acid sequence shown in SEQ ID NO.2, and has any of the following functions:

[0056] (1) Inhibit RINL gene expression;

[0057] (2) Deletion or silencing of the RINL gene;

[0058] (3) knockout of the RINL gene;

[0059] (4) Antagonize RINL protein.

[0060] In some embodiments, the prevention and / or reduction of diabetes risk is achieved by improving glucose tolerance or improving the degree of insulin resistance.

[0061] In some embodiments, the improving immune function of obese patients is to reduce inflammation in their adipose tissue.

[0062] In some embodiments, the RINL antagonist is selected from shRNA, siRNA, miRNA, dsRNA, stRNA, a small molecule compound, an aptamer, or an antibody or an antigen-binding fragment thereof.

[0063] In some embodiments, the antibody or antigen-binding fragment thereof is selected from a whole antibody, a F(ab)-fragment, a F(ab)2-fragment, a single-chain antibody, a chimeric antibody, a bivalent antibody-construct, a synthetic antibody, a bispecific single-chain antibody or a cross-cloned antibody.

[0064] In some embodiments, the RINL antagonist is a RINL antibody. In some embodiments, the RINL antagonist is a siRNA, the siRNA comprising a sense strand and an antisense strand, which are 15-30 base pairs in length, and the antisense strand comprises a complementary region complementary to an mRNA encoding RINL.

[0065] In some embodiments, the nucleotide sequence of the siRNA is selected from any one of the following combinations of sense strands and antisense strands:

[0066] (1) a sense strand having a sequence as shown in SEQ ID NO.3, and an antisense strand having a sequence as shown in SEQ ID NO.4; or

[0067] (2) a sense strand having a sequence as shown in SEQ ID NO.5, and an antisense strand having a sequence as shown in SEQ ID NO.6; or

[0068] (3) A sense strand having the sequence shown in SEQ ID NO.7, and an antisense strand having the sequence shown in SEQ ID NO.8.

[0069] In some embodiments, the RINL antagonist is capable of reducing the accumulation of subcutaneous fat and visceral fat.

[0070] In some embodiments, the medicament includes an active ingredient, a RINL antagonist, and a pharmaceutically acceptable carrier or excipient.

[0071] In some embodiments, the content of the RINL antagonist in the drug is 1% to 99%.

[0072] On the other hand, the present disclosure provides a method for screening drugs for treating and / or preventing obesity, which comprises the following steps: detecting changes in the expression level of RINL gene in the body before and after administration.

[0073] In another aspect, the present disclosure provides a pharmaceutical composition for treating and / or preventing obesity, comprising a RINL antagonist that inhibits RINL expression, and optionally a pharmaceutically acceptable carrier or excipient.

[0074] In some embodiments, the pharmaceutical composition further comprises one or more additional therapeutic components.

[0075] On the other hand, the present disclosure provides a RINL antagonist, wherein the RINL antagonist specifically targets the nucleotide sequence shown in SEQ ID NO.1 or specifically binds to the amino acid sequence shown in SEQ ID NO.2, and has any of the following functions:

[0076] (1) Inhibit RINL gene expression;

[0077] (2) Deletion or silencing of the RINL gene;

[0078] (3) knockout of the RINL gene;

[0079] (4) Antagonizing RINL protein. In some embodiments, the RINL antagonist is siRNA, the siRNA comprises a sense strand and an antisense strand, and the length of the siRNA is 15-30 base pairs, and the antisense strand comprises a complementary region complementary to the mRNA encoding RINL.

[0080] In some embodiments, the nucleotide sequence of the siRNA is selected from any one of the following combinations of sense strands and antisense strands:

[0081] (1) a sense strand having a sequence as shown in SEQ ID NO.3, and an antisense strand having a sequence as shown in SEQ ID NO.4; or

[0082] (2) a sense strand having a sequence as shown in SEQ ID NO.5, and an antisense strand having a sequence as shown in SEQ ID NO.6; or

[0083] (3) A sense strand having the sequence shown in SEQ ID NO.7, and an antisense strand having the sequence shown in SEQ ID NO.8.

[0084] In another aspect, the present disclosure provides nucleic acids encoding the aforementioned RINL antagonists.

[0085] In another aspect, the present disclosure provides an expression vector comprising the aforementioned nucleic acid.

[0086] In another aspect, the present disclosure provides a cell comprising the aforementioned nucleic acid and an expression vector.

[0087] In another aspect, the present disclosure provides a composition comprising the aforementioned RINL antagonist, and optionally a pharmaceutically acceptable carrier or excipient.

[0088] In another aspect, the present disclosure provides a use of the aforementioned use, the aforementioned RINL antagonist and / or the aforementioned composition in the preparation of a medicament for treating and / or preventing obesity in an individual, wherein the medicament is administered to the individual in an effective amount.

[0089] In another aspect, the present disclosure provides a method for treating obesity by administering a therapeutically effective amount of the aforementioned RINL antagonist and / or the aforementioned composition to a subject.

[0090] Example

[0091] A further understanding of the present disclosure may be obtained by reference to some specific embodiments given herein, which are only used to illustrate the present disclosure and are not intended to limit the scope of the present disclosure in any way. Obviously, various modifications and variations may be made to the present disclosure without departing from the essence of the present disclosure, and therefore, these modifications and variations are also within the scope of the present application. The clinical trial data used in the present disclosure have been obtained with the knowledge and consent of the subjects.

[0092] Example 1: RINL gene is associated with obesity

[0093] Obesity is affected by epigenetic and environmental factors. In order to discover new genetic genes related to obesity as therapeutic targets for alleviating obesity, the applicant analyzed the transcriptome data of the population in the EGO database and unexpectedly found that the transcription level of RINL in human subcutaneous adipose tissue was positively correlated with cholesterol and triglycerides in their serum. Figure 1 As shown, with the increase of RINL expression, cholesterol and triglyceride tend to increase. Cholesterol and triglyceride are blood lipid indicators, revealing that RINL gene may be related to obesity.

[0094] In order to further demonstrate the relationship between the RINL gene and obesity, the applicant used the 3T3-L1 preadipocyte cell line to induce adipocyte differentiation. During the differentiation process, adipocytes are in the process of continuously accumulating fat content. Sampling was performed at different time points of adipocyte lipid accumulation. It was found that as the degree of lipid accumulation continued to increase, the expression level of RINL also increased, proving that the gene has a significant correlation with the degree of obesity. At the same time, C57BL / 6 wild-type mice were fed 60% high-fat feed to construct a high-fat animal model, and a blank control group (i.e., normal diet for mice) was set up to detect the expression of RINL in the epididymal adipose tissue of mice and in the in vitro adipocyte model. The results are shown in Figure 2 It was found that compared with the control group, the expression level of RINL in the fat of obese mice induced by high-fat feeding was significantly increased, which also proved that the RINL gene has a significant positive correlation with the degree of obesity and can be used as a target for studying obesity models.

[0095] Example 2: Knocking down the expression of RINL in HepG2 cells using siRNA can alleviate lipid deposition in HepG2 cells

[0096] Considering that the expression of RINL gene is positively correlated with the degree of obesity, in order to verify whether knocking down the expression of RINL can alleviate the level of obesity, the applicant first demonstrated in a cell model, using HepG2 cells, which are human hepatocytes and are the most common cell model for liver disease-related research. Three groups of siRNAs targeting RINL were designed, and their sequence information is shown in Table 1 below. RINL was knocked down by siRNA through liposome transfection. HepG2 cells were lysed to collect proteins, and the expression level of RINL in cells was analyzed by immunoblotting. The results are shown in 3A, and siRNA significantly reduced the expression of RINL in cells. In addition, after knocking down RINL in HepG2 cells by siRINL through liposome transfection, the cells were subjected to high-lipid modeling (using 500 μmol / L oleic acid and 250 μmol / L palmitic acid to treat the cells for 24 hours), and the triglyceride level in the cells was detected by a triglyceride detection kit (Jizhi Biochemical; AC10179), and the cells were stained with Oil Red O (Nanjing Jiancheng; D027-1-2) to observe lipid accumulation. The test results are shown in Figure 3 B and 3C, it can be seen that the treatment with oleic acid and palmitic acid caused a significant increase in the intracellular triglyceride content and lipid accumulation, while knocking down the expression of RINL can alleviate the abnormal increase in triglyceride content and lipid accumulation caused by oleic acid and palmitic acid treatment, and there is a tendency for the cells to return to normal levels. That is, the reduced expression of RINL can enable HepG2 cells to resist the abnormal increase in lipids caused by high-fat modeling, and the low expression of RINL helps to alleviate obesity.

[0097] Table 1 Sequence information of siRINL

[0098]

[0099] Example 3: RINL-KO mice resist obesity induced by a high-fat diet

[0100] The conclusions obtained in the cell model need to be further verified in the mouse model. Because the low expression of RINL is related to resistance to obesity, we constructed mice with systemic knockout of RINL and found that this gene knockout had no significant effect on the growth and development of mice. We selected 4 female mice and 8 male mice aged 8 weeks, and 8 normal female mice and 8 male mice, and set them as blank control group (WT-NCD), positive control group (WT-HFD) and experimental group (KO-HFD). The positive control group and the experimental group were induced with a high-fat diet (i.e., 60% high-fat feed). The blank group was fed normally, and the high-fat treatment was carried out for 13 weeks. The weight changes, body fat percentage and food intake of each group of mice were dynamically monitored for 24 hours. The results are shown in the table. Figure 4After 13 weeks of culture, the weight gain of the positive control group mice in both female and male mice was the fastest, which was significantly different from the experimental group in which RINL was knocked out. Similarly, when the amount of physical intake was basically the same, the body fat rate of the mice in the positive control group was also the highest, especially in female mice, whose body fat rate was nearly twice that of the experimental group. The above experiments show that RINL-KO has a significant ability to resist the weight gain caused by a high-fat diet. It also improved the body fat rate of mice without affecting the food intake of mice.

[0101] Example 4: RINL-KO improves the metabolic capacity of high-fat diet obese mice

[0102] In order to explore whether RINL knockout can improve the metabolic status of mice, this example set up a positive control group (wild-type mice-high-fat diet) and an experimental group (RINL gene knockout mice-high-fat diet), and used a 16-channel metabolic monitoring system to monitor the metabolic status of mice. The results are shown in Figure 5 Regardless of day or night, regardless of female or male, the 24-hour oxygen consumption of RINL knockout mice on a high-fat diet was significantly higher than that of wild-type mice on a high-fat diet. This indicates that knocking out the RINL gene improved the oxygen consumption level of female and male mice, that is, improved the metabolism of mice, making the metabolism of mice more vigorous, so the excessive weight gain of mice can be alleviated.

[0103] Example 5: RINL-KO improves glucose tolerance and insulin resistance in mice fed a high-fat diet

[0104] Glucose metabolism is also an important part of the obesity process. Further, this example explores whether RINL knockout can improve glucose tolerance in mice. The oral glucose tolerance test (OGTT) is a glucose load test used to understand the function of pancreatic β cells and the body's ability to regulate blood sugar. It is a commonly used clinical test for diagnosing diabetes and is currently the internationally recognized gold standard for diagnosing diabetes and abnormal glucose regulation. On the contrary, if insulin is given exogenously and blood sugar levels are tested over a specific period of time, it is the insulin tolerance test ("insulintolerance test, insulin-induced hypoglycemia test"), referred to as "ITT", and the administration of exogenous insulin is achieved through intraperitoneal injection; if insulin insensitivity occurs, blood sugar will drop relatively slowly and rise faster after insulin injection.

[0105] Female and male mice were selected as blank control group (wild-type mice-normal diet), positive control group (wild-type mice-high-fat diet) and experimental group (RINL gene knockout mice-high-fat diet), and OGTT and ITT tests were performed on them respectively. The results are shown in Figure 6 and Figure 7 .

[0106] Depend on Figure 6 It can be seen that compared with the positive control group, RINL-KO significantly improved the glucose tolerance of female mice. Although the blood glucose changes of male mice in the RINL-KO group were not much different from those in the positive control group, the area under the blood glucose curve (AUC) showed that RINL gene knockout still improved the overall changes in blood glucose concentration over time in mice.

[0107] Depend on Figure 7 It can be seen that compared with the positive control group, RINL-KO significantly improved the insulin resistance of female and male mice. Similarly, the improvement effect in female mice was better.

[0108] In summary, RINL-KO can improve the glucose tolerance and insulin resistance of mice, that is, improve the overall health of mice.

[0109] Example 6: RINL-KO improves the accumulation of subcutaneous fat and visceral fat in mice fed a high-fat diet

[0110] After the in vivo experiment on mice, the mice in the above groups were killed and samples were collected to detect molecular indicators of various organs and explore possible molecular mechanisms. Specifically, the female and male mice in the blank control group (wild-type mice-normal diet), positive control group (wild-type mice-high-fat diet) and experimental group (RINL gene knockout mice-high-fat diet) were induced with a high-fat diet, and their individual volumes were observed and photographed. They were then killed, and their subcutaneous fat tissues and organs were taken to analyze and compare the fat content and organ proportions of each group. The results are shown in Figure 8 and Fig. 9 The liver, brown adipose tissue and gonadal white adipose tissue of each group of mice were collected for HE sectioning. The changes in the morphology of each tissue were observed by sectioning and HE staining. The results are shown in Fig.10 and Fig.11 .

[0111] Depend on Figure 8 It can be seen that under the high-fat diet, the volume of the positive control group mice was much larger than that of the experimental group mice. At the same time, the lipid accumulation of their subcutaneous inguinal white fat and visceral gonadal white fat was also much greater than that of the experimental group mice. Similarly, the liver volume was also larger than that of the experimental group mice, probably because of the greater accumulation of visceral fat. The above results show that RINL-KO significantly improved the accumulation of subcutaneous fat and visceral fat in female and male mice.

[0112] Fig. 9 The weight ratio of each organ in each group of mice was counted, and the results further showed that RINL-KO significantly improved the proportion of internal organs in female and male mice, that is, improved their visceral fat accumulation and improved their health.

[0113] Depend on Fig.10 and Fig.11 The results of pathological observation of fat sections of each part of each group of mice showed that in the high-fat obesity model, the lipid accumulation in the liver, brown fat, and white fat of both male and female RINL-KO mice was reduced compared with the control group, and the size of fat cells in female mice was reduced more significantly.

[0114] In summary, RINL-KO can improve the accumulation of subcutaneous fat and visceral fat in mice fed a high-fat diet, helping to maintain the health of mice.

[0115] Example 7: RINL-KO reduces adipose tissue inflammation caused by obesity in mice fed a high-fat diet

[0116] RINL-KO showed significant improvement in obesity in adipose tissue. We further observed the liver (high-fat diet can induce significant fatty liver phenotype, and observed whether RINL-KO can alleviate this phenotype). The livers of female mice in each experimental group were selected for Oil Red O staining (Nanjing Jiancheng; D027-1-2), and F4 / 80 antibody was used to mark macrophages in the gonadal white adipose tissue for immunofluorescence staining. The test results are shown in Fig.12 .

[0117] Compared with the positive control group, the ectopic accumulation of lipids in the liver of RINL-KO mice was reduced, and the liver fat content was close to that of the blank control group. At the same time, the amount of macrophage infiltration in the adipose tissue of RINL-KO mice was significantly lower than that of the positive control group, indicating that the knockout of the RINL gene reduced the adipose tissue inflammation caused by obesity in mice fed a high-fat diet.

[0118] Example 8: RINL-KO enhances mitochondrial function in brown fat and liver tissues of mice fed a high-fat diet

[0119] To further explore the molecular mechanism, we speculated that RINL-KO enhanced mouse metabolism and alleviated mouse obesity, which was closely related to mitochondrial function. Therefore, we selected brown adipose tissue and liver tissue from the positive control group (wild-type mice-high-fat diet) and the experimental group (RINL knockout mice-high-fat diet) to measure the oxygen consumption in each tissue. The mitochondrial function analyzer Oroboros O2K was used to measure the oxygen consumption rate of fresh brown fat and liver homogenates. By adding substrates of mitochondrial complexes I and II to reach the maximum respiration value, and then adding inhibitors of complexes I and III in turn to inhibit mitochondrial respiration, the difference is the function of the corresponding mitochondrial complex, and finally using the substrate of complex IV to directly provide electrons for complex IV to obtain the oxygen consumption of complex IV.

[0120] The experimental results are shown in Fig.13 The oxygen consumption level was measured using O2K on tissue homogenates of tissues of the same weight. Compared with WT, the mitochondrial functions of BAT and part of the liver in RINL-KO were upregulated, indicating that RINL knockout can enhance the mitochondrial functions of part of the brown fat and liver.

[0121] Example 9: RINL-KO increases the oxygen consumption respiration rate of brown fat primary cells in mice fed a high-fat diet

[0122] In order to further refine the molecular mechanism, we used the more detailed cellular energy metabolism instrument seahorse XFe24 at the cellular level to further analyze the oxygen consumption rate of brown fat primary cells in the positive control group (wild-type mice-high-fat diet) and the experimental group (RINL gene knockout mice-high-fat diet). Oligomycin was added to inhibit ATP synthase activity, and FCCP was added to inhibit the coupling of ATP synthesis and electron transfer, so that the oxygen consumption rate reached the maximum value, and then the inhibitors of complex I and III were added to completely inhibit the entire mitochondrial respiration. The results are shown in Fig.14 It can be seen that the oxygen consumption respiratory rate of primary brown fat cells increased after RINL knockout.

[0123] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0124] The above-mentioned embodiments only express several implementation methods of the present disclosure, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present disclosure, and these all belong to the protection scope of the present disclosure. Therefore, the protection scope of the patent of the present disclosure shall be subject to the attached claims.

[0125] Table 2 Sequence information

[0126]

[0127]

Claims

1. Use of the RINL gene or its encoded protein, wherein the RINL gene or its encoded protein: (1) is used as a marker for diagnosing, detecting or prognosing obesity; (2) is used to prepare a reagent or kit for diagnosing or detecting obesity; or (3) is used to prepare a drug for treating obesity.

2. Use of a RINL antagonist in the preparation of a drug for: (1) preventing and / or treating obesity; (2) improving the metabolic capacity of obese patients; (3) preventing and / or reducing the risk of diabetes in obese patients; or (4) improving the immune function of obese patients.

3. The use according to claim 2, wherein The RINL antagonist specifically targets the nucleotide sequence shown in SEQ ID NO.1 or specifically binds to the amino acid sequence shown in SEQ ID NO.2, and has any of the following functions: (1) Inhibit RINL gene expression; (2) Deletion or silencing of the RINL gene; (3) knockout of the RINL gene; (4) Antagonize RINL protein.

4. The use according to claim 2 or 3, wherein The RINL antagonist is selected from shRNA, siRNA, miRNA, dsRNA, stRNA, a small molecule compound, an aptamer, or an antibody or an antigen-binding fragment thereof.

5. The use according to any one of claims 2 to 4, wherein The antibody or antigen-binding fragment thereof is selected from the group consisting of a whole antibody, a F(ab)-fragment, a F(ab)2-fragment, a single-chain antibody, a chimeric antibody, a bivalent antibody-construct, a synthetic antibody, a bispecific single-chain antibody or a cross-cloned antibody.

6. The use according to any one of claims 2 to 5, wherein The RINL antagonists reduce the accumulation of subcutaneous and visceral fat.

7. The use according to any one of claims 2 to 6, wherein The medicine comprises an active ingredient, a RINL antagonist, and a pharmaceutically acceptable carrier or excipient.

8. The use according to any one of claims 2 to 7, wherein The content of the RINL antagonist in the medicine is 1% to 99%.

9. A method for screening drugs for treating and / or preventing obesity, comprising the following steps: detecting changes in the expression level of RINL gene in the body before and after administration.

10. A pharmaceutical composition for treating and / or preventing obesity, comprising a RINL antagonist that inhibits RINL expression, and optionally a pharmaceutically acceptable carrier or excipient; Preferably, the pharmaceutical composition further comprises one or more additional therapeutic ingredients.

Citation Information

Cited By

  • Application of GDI2 as weight-losing target and method for screening obesity treatment drugs

    CN120683247A

  • Use of RINL gene and antagonist thereof in treatment of obesity

    WO2026026922A1